Regeneron's Eylea under FDA review for macular edema after BRVO
This article was originally published in Scrip
Executive Summary
The FDA has accepted Regeneron Pharmaceuticals supplemental biologics license application (sBLA) under a standard review for Eylea (aflibercept) as a treatment for macular edema following branch retinal vein occlusion (BRVO) – setting 23 October as the Prescription Drug User Fee Act action date.